News
SGP
27.07
-2.10%
-0.58
Weekly Report: what happened at SGP last week (0914-0918)?
Weekly Report · 5d ago
Weekly Report: what happened at SGP last week (0907-0911)?
Weekly Report · 09/14 10:36
Weekly Report: what happened at SGP last week (0831-0904)?
Weekly Report · 09/07 10:28
Weekly Report: what happened at SGP last week (0824-0828)?
Weekly Report · 08/31 10:37
Weekly Report: what happened at SGP last week (0817-0821)?
Weekly Report · 08/24 10:38
Weekly Report: what happened at SGP last week (0810-0814)?
Weekly Report · 08/17 10:39
SpyGlass Pharma initiated with an Outperform at Raymond James
TipRanks · 08/16 13:48
This Aehr Test Systems Analyst Begins Coverage On A Bearish Note; Here Are Top 4 Initiations For Friday
Benzinga · 08/14 12:57
SpyGlass Pharma Initiated at Outperform by Raymond James
Dow Jones · 08/14 10:57
SpyGlass Pharma Price Target Announced at $39.00/Share by Raymond James
Dow Jones · 08/14 10:57
Analysts Offer Insights on NA Companies: Ottobock SE & Co. KGaA (OtherOBCKF), SpyGlass Pharma (Nasdaq: SGP) and Figure Technology Solutions, Inc. Class A (FIGR)
TipRanks · 08/14 10:50
Raymond James Initiates Coverage On SpyGlass Pharma with Outperform Rating, Announces Price Target of $39
Benzinga · 08/14 10:47
Weekly Report: what happened at SGP last week (0803-0807)?
Weekly Report · 08/10 10:33
SpyGlass Pharma: Buy Rating Reiterated as Late-Stage Glaucoma Pipeline Advances; $37 Price Target Maintained
TipRanks · 08/07 20:45
SpyGlass Pharma Q2 GAAP EPS of -$0.59
Seeking Alpha · 08/07 16:10
SpyGlass Pharma reports Q2 EPS (59c), consensus (55c)
TipRanks · 08/06 20:51
SpyGlass Pharma, Inc. Loss At -$19.864 Mln In Q2
NASDAQ · 08/06 20:24
Press Release: SpyGlass Pharma Reports Second -2-
Dow Jones · 08/06 20:05
SpyGlass Pharma Insiders Enjoying US$1.1m Appreciation On US$2.16m Investment
Simply Wall St · 08/05 11:09
Weekly Report: what happened at SGP last week (0727-0731)?
Weekly Report · 08/03 10:32
More
Webull provides a variety of real-time SGP stock news. You can receive the latest news about SpyGlass Pharma, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SGP
SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.